摘要
目的探讨恩替卡韦联合阿德福韦治疗乙型肝炎肝硬化失代偿期的临床效果。方法选择患者60例,分为两组,每组各30例,在常规治疗的基础上,观察组采用恩替卡韦联合阿德福韦治疗,对照组则单纯采用阿德福韦治疗,两组均连续治疗48周(1个疗程)。比较两组治疗后的丙氨酸氨基转移酶、天冬氨酸氨基转移酶、HBV DNA水平变化情况以及治疗期间出现的不良反应。结果观察组治疗后的丙氨酸氨基转移酶、天冬氨酸氨基转移酶、HBV DNA水平显著低于对照组(P<0.05);观察组治疗期间出现消化道出血、失眠、疲倦和肝性脑病的比率均显著低于对照组(P<0.05)。结论恩替卡韦联合阿德福韦治疗乙型肝炎肝硬化失代偿期能有效改善患者的肝功能、睡眠质量,延缓肝硬化,避免和减少肝癌的发生。
Objective To discuss the clinical effect of entecavir combined with adefovir treating decompensated liver cirrhosis of type B hepatitis. Methods 60 cases were selected and divided into the two groups,there were 30 cases in each group.All patients were given the conventional treatment,then the observation group were given entecavir combined with adefovir,the control group was given adefovir only,both groups were treated for 48 weeks（a course of treatment）, the level of alanine aminotransferase,aspartate aminotransferase and HBV DNA,adverse reaction during treatment in the two groups were compared. Results The level of alanine aminotransferase,aspartate aminotransferase and HBV DNA in the observation group after treatment were obviously lower than those in the controlgroup（P〈0.05）;the ratio of gastrointestinal bleeding, insomnia,fatigue and hepatic encephalopathy during treatment were significantly lower than those in control group（P〈0.05）. Conclusion Adefovir combined with entecavir therapy treating decompensated liver cirrhosis of type B hepatitis can effectively improve liver function and sleep quality of patients,slow cirrhosis,avoid and reduce the incidence of liver cancer.
出处
《中国当代医药》
2014年第20期79-81,共3页
China Modern Medicine
基金
广东省梅州市医药研究课题(2011-B-61)
关键词
恩替卡韦
阿德福韦
乙型肝炎
肝硬化
失代偿
Entecavir
Adefovir
Type B hepatitis
Liver cirrhosis
Decompensated
